Evidence map›Paper›PMID 42295358›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

Blue laser turbinate reduction with vs. without posterior nasal neurolysis for refractory rhinitis: a retrospective comparative study.

Cheng-Jung Wu, Sheng-Yu Wu, Cheng-Yu Tsai, Arnab Majumdar, Jeffrey Yang, Jinn-Moon Yang, Lok-Yee Joyce Li

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cheng-Jung WuDepartment of Otolaryngology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Sheng-Yu WuDepartment of Industrial Engineering and Industrial Management, National Tsing Hua University, Hsinchu, Taiwan.
Cheng-Yu TsaiDepartment of Civil and Environmental Engineering, Imperial College London, London, UK.
Arnab MajumdarDepartment of Civil and Environmental Engineering, Imperial College London, London, UK.
Jeffrey YangDepartment of Biology, University of California, Riverside, USA.
Jinn-Moon YangInstitute of Bioinformatics and Systems Biology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
Lok-Yee Joyce LiDepartment of Industrial Engineering and Industrial Management, National Tsing Hua University, Hsinchu, Taiwan. b101102173@tmu.edu.tw.

Funding

National Science and Technology Council 114-2314-B-038-117.Taipei Medical University TMU113-AE1-B04
6 · The paper itself

Abstract

backgroundChronic rhinitis that does not respond well to drug therapy remains a major challenge in clinical treatment. Inferior turbinate reduction can improve nasal obstruction symptoms, while posterior nasal nerve (PNN) ablation can reduce symptoms caused by neurogenic hypersecretion. Blue laser technology provides precise tissue coagulation and minimizes intraoperative bleeding.

methodsThis retrospective comparative study, conducted at Shuang Ho Hospital between 2024 and 2025, aimed to compare the efficacy and safety of blue laser inferior turbinate reduction (BITR) combined with blue laser posterior nasal nerve neurolysis (BPN3) versus BITR alone. A total of Ninety-nine adult patients with chronic rhinitis who had not responded adequately to at least three months of drug therapy (≥ 3 months) were included. Among them, forty-eight patients received BITR combined with BPN3, and fifty-one patients received BITR only. The primary endpoints were the 24-hour reflective total nasal symptoms score (rTNSS) and the nasal obstruction symptoms evaluation scale (NOSE) score, which were compared and analyzed at baseline, 1 month and 6 months postoperatively.

resultsAt 6 months post-surgery, the mean Responsive Total Nasal Symptom Score (rTNSS) decreased by 77.6% in the BITR combined with BPN3 group (from 7.6 ± 1.9 to 1.7 ± 1.6), while the BITR alone group saw a 48% decrease (from 7.5 ± 1.6 to 3.9 ± 1.7), with a statistically significant difference between the two groups (p < 0.05). The Nasal Obstruction Symptom Assessment Scale (NOSE) scores improved by 91.9% and 85.5%, respectively, with a statistically significant difference between the two groups (p < 0.05). Overall, no serious complications occurred during the study period.

conclusionBlue laser posterior nasal nerve neurolysis combined with inferior turbinate reduction provides superior symptom relief compared with BITR alone, particularly for rhinorrhea, with excellent safety and tolerability. This dual-target approach offers a promising minimally invasive treatment for medication-refractory chronic rhinitis.

Indexed as

Laser TherapyNasal ObstructionNerve BlockRhinitisTurbinatesAdultChronic DiseaseCombined Modality TherapyFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeBlue laserChronic rhinitisNeurolysisPosterior nasal nerverTNSSTurbinate reduction

Identifiers

PMID42295358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.